Saturday, September 9
 
10:00 am - 04:00 pm Live Surgery
05:00 pm - 07:00 pm Fluorescein Angiography & Surgical Case Conference
08:00 pm - 11:00 pm Welcome Reception and Dinner

            

Sunday, September 10

 
08:00 Opening of continuing Film Projection
08:00 Opening Remarks Julia Haller, Didier Ducournau & Jean-Paul Amar
 
08:05 Symposium I: Anti-Angiogenesis (Part 1) Presiding Officer: Susan B; Bressler Chair: Ursula Schmidt-Erfurth Moderator: Tom S. Chang
 
08:05

Combined efficacy of intravitreal ranibizumab in two Phase III studies of CNV secondary to ARMD Anat Loewenstein

08:12 Combined Safety of Intravitreal Ranibizumab in Two Phase III Studies of CNV Secondary to ARMD Paolo Lanzetta
08:19 Two-year efficacy and safety results from the MARINA study Ursula Schmidt-Erfurth
08:26 Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 Phase III and IIIB studies of patients with CNV secondary to AMD Jean-Francois Korobelnik
08:33 Discussion
08:37 Intravitreal Ranibizumab (LucentisTM) plus Verteporfin PDT for Neovascular ARMD: FOCUS 2-year Results Andrew Antoszyk
08:44 PIER: Year 1 Results of a Phase IIIB Study of Ranibizumab Efficacy and Safety in CNV Due to ARMD Prema Abraham
08:51 Pier: Year 1 FA/OCT Results in a study of Ranibizumab (Lucentis™) for CNV Due to ARMD William F. Mieler
08:58 An OCT-Guided Variable-Dosing Regimen with Lucentis™ (Ranibizumab) in Neovascular AMD: One Year Results from the PrONTO Study Philip J. Rosenfeld
09:05 Discussion
09:10 Introduction of Featured Guest Lecture: Judah Folkman Presiding Officers: Didier Ducournau, Julia Haller and Gene de Juan
09:15 Potential Future Advances in Ophthalmology from Research in Tumor Angiogenesis Judah Folkman, MD
10:00 Discussion
10:05 Poster Session (AMD/ANTI-ANGIOGENESIS)
 
10:40 Symposium II: Anti-Angiogenesis (Part 2) Presiding Officer: Lawrence Singerman Chair: David Williams Moderators: Frank Koch
 
10:40 Open-label, multicenter, Phase II Study Assessing the safety and efficacy of same-day Verteporfin and liquid ranibizumab 0.5mg (PROTECT study) Sebastian Wolf
10:47 Ranibizumab (Lucentis) Vision-Specific Quality of Life Trough 24 Months in Neovascular ARMD Subjects in Marina: A Phase III Clinical Trial Tom S. Chang
10:54 Vision-Specific Quality of Life at 12 Months in Predominantly Classic Neovascular ARMD in Anchor: A Phase III Trial of Ranibizumab and Verteporfin PDT Neil M. Bressler
11:01 The Value and Cost-Effectiveness of Interventions for Subfoveal Neovascular ARMD Melissa Brown
11:08 Discussion
11:12 Intravitreally Injected Anti-VEGF Drugs Exert a Biological Effect in the Fellow Eye Tongalp Tezel
11:16 Pharmacokinetics of Intravitreal Bevacizumab (Avastin) Sophie J. Bakri
11:20 Vitreous Levels of Unbound Bevacizumab and Unbound Vascular Endothelial Growth Factors in Two Human Subjects Paul M. Beer
11:24 Stability of bevacizumab (Avastin) after withdrawal into a syringe and refrigeration or freezing Colin A. McCannel
11:28 Discussion
11:31 Intravitreal Bevacizumab for the treatment of CNV secondary to Ocular Histoplasmosis and Multifocal Choroiditis Sundeep Dev
11:36 Short-Term Outcomes in over 500 Intravitreal Bevacizumab Treatments for Retinal or CVD at the New York Eye & Ear Infirmary Thomas O. Muldoon
11:41 Intravitreal Bevacizumab As Isolated First Line Therapy In Patients With New Untreated CNV Membranes Alay Banker
11:46 Six-month Follow up on 50 Consecutive Patients with Intravitreal Bevacizumab Injections for Neovascular ARMD Samira Khan
11:51 Discussion
11:55 Primary Intravitreal Bevacizumab (Avastin) for the Treatment of CNV secondary to ARMD: Results of the Pan-American Collaborative Retina Study Group Jans Fromow-Guerra
12:00 Intravitreal Bevacizumab (Avastin) for the Treatment of Neovascular ARMD Alessandro Castellarin
12:05 Intravitreal Bevacizumab (Avastin™) for Primary Treatment of Neovascular ARMD David F. Williams
12:10 Intravitreal Bevacizumab (Avastin) Treatment of CNV Secondary to ARMD Richard F. Spaide
12:15 Discussion
12:18 Time to recurrence of ARMD-related CNV leakage after a single initial intravitreous injection bevacizumab (Avastin®): Implications for a retreatment Edgar L. Thomas
12:23 A FA/ICG analysis of the retinal/choroidal vasculature and CNV membrane complex six months following intravitreal Avastin injections Paul E. Tornambe
12:28 Intravitreal Bevacizumab Compared with PDT for Juxtafoveal CNV Membranes in ARMD Derek Barker
12:33 Combination therapy for wet ARMD using verteporfin PDT and intravitreal bevacizumab Jose Dalma-Weiszhausz
12:38 Discussion
12:41 Combined PDT with Verteporfin and Intravitreal Bevacizumab for CNV in ARMD Gaurav K. Shah
12:46 Combined PDT with Verteporfin and Intravitreal Bevacizumab for Subfoveal CNV in ARMD David Misch
12:51 Combination Avastin and Reduced Fluence PDT for CNV David Callanan
12:56 Intravitreal Bevacizumab (Avastin) enhanced Pegaptanib (Macugen) therapy for CNV in ARMD: An Avastin Booster Michael J. Tolentino
01:01 Vitrectomy in Triple Therapy for CNV Frank H.J. Koch
01:06 Discussion
01:10 Young Physicians Section' Lunch
  Crystal Apple Lecture: Controversies in the Management and Prevention of Endophthalmitis Harry W. Flynn, MD
 
02:40 Symposium III: Anti-Angiogenesis (Part 3) Presiding Officer: Paul E. Tornambe Chair: Anthony Adamis Moderator: Albert Augustin
 
02:40 C.L.E.A.R. - IT 1: A Phase I Safety, Tolerability, and Bioactivity Study of Intravitreal VEGFTrap in Patients with Neovascular ARMD Quan Dong Nguyen
02:47 VEGF small interfering (si) RNA, for Treatment of Wet ARMD Lawrence J. Singerman
02:54 The Effects of Combined Inhibition of PDGF-B and VEGF-A Signaling in Murine Models of Ocular Neovascularization Anthony Adamis
03:00 The Role of a Selective VEGF Blockade in ARMD Thomas R. Friberg
03:06 Anecortave Acetate Clinical Update Peter K. Kaiser
03:12 Discussion
03:16 Combined IVT with PDT for the treatment of CNV in ARMD Catherine Favard
03:22 The effect of Kenalog as adjunctive treatment to Visudyne in minimally classic and occult neovascular ARMD: A prospective, randomized clinical trial Tom Sheidow
03:28 Six-month Results of a Randomized, Double-Masked, Controlled Trial of IVT as an Adjunct to PDT in Predominantly Classic Neovascular ARMD. The Canadian RETINA Study David Maberley
03:34 Large case series of different types of CNV after Combination Treatment (PDT with intravitreal Triamcinolone) Albert J. Augustin
03:40 Discussion
03:45 AMD-panel Moderator: Philip J. Rosenfeld
 
Monday, September 11
 
08:00 Opening of continuing Film Projection
 
08:00
Awards & Special Presentations Presiding Officers: Julia Haller, Gene de Juan, and George Williams
 
08:00
Introduction of Pyron Award Winner Brooks W. McCuen, II
08:05 Pyron Award Lecture: Evolving Concepts in Pharmacologic Vitreolysis Brooks W. McCuen, II
08:35 Introduction of Founders Award Winner Kirk H. Packo
08:40
Founders Award Lecture: Vitrectomy Technology - Where We've Been. Where We Are. Where We Are Going. Kirk H. Packo
09:10 Pay for Performance: A True Quality Initiative or a Means of Cost Control William L. Rich, III
09:20 American Retina Foundation Roy A. Levit
09:25 Young Phisicians Section's Crystal Apple Award Presentation
09:27 PAT Survey Award
09:30
ASRS Business Meeting
10:00
Break/Exhibits/Poster Session (IMAGING/SURGICAL DEVICES & INSTRUMENTATION/PHARMACOLOGY/SOCIOECONOMICS)
 
10:40
Symposium IV: Imaging and AMD Presiding Officer: Giovanni Staurenghi , Chair: Claude Boscher, Moderator: Gregg Kokame
 
10:40 Retinal Measurements with 3D-OCT Alexander C. Walsh
10:45
SOCT “Copernicus” a new diagnostic tool in retinology Jerzy Nawrocki
10:50
Active CNV Without Subretinal or Intraretinal Fluid on OCT Imaging G. Baker Hubbard
10:55
Dualing OCT Modalities: Contrasting Retinal Features Revealed by a Dual Mode High Speed Ultrahigh Resolution Spectral and Temporal OCT/SLO Imager Richard B. Rosen
11:00
Spectral Domain OCT Provides New Insight Into the Extent of Macular Pathology in ARMD Cynthia A. Toth
11:05
Discussion
11:08
AMD, hypertension and potential cardiovascular risks with intravitreal Avastin injection Claude Boscher
11:13
Humanistic Burden and Health Resource Utilization in Neovascular ARMD Patients from Five Countries Gisele Soubrane
11:17
Comparison of Comorbid Conditions Between Wet ARMD Patients and a Control Cohort in the Medicare Population Gergana Zlateva
11:22
Myocardial Infarction and Cerebrovascular Accident Rates in Patients with Neovascular ARMD in a Healthcare Claims Database Emily S. West
11:27 Annual Rates of Cardiovascular Events in Medicare Neovascular ARMD Patients Tsontcho Ianchulev
11:32
Discussion
11:36
Long Term Results of the Age-Related Eye Disease Study Emily Y. Chew
11:41
Vitamin Usage Patterns in the Prevention of Advanced ARMD in a Tertiary Care Population Susan B. Bressler
11:46
Discussion
11:51
Effect of Initial Visual Acuity on Visual Loss in Untreated ARMD Eyes with Subfoveal Neovascularization Lucian Del Priore
11:56
Incident CNV Lesions in the Fellow Eyes of Participants with Unilateral Neovascular ARMD during the Submacular Surgery Trials Sharon D. Solomon
12:01 Quantitative OCT Sub-Analysis in Neovascular ARMD SriniVas Sadda
12:06 Treatment of Retinal Angiomatous Proliferation Lesions Associated with Pigment Epithelial Detachment with Focal Pulsed Laser Robert P. Murphy
12:11 Results of a 1 Year Study of Feeder Vessel Therapy in ARMD Giovanni Staurenghi
12:15 Discussion
12:18 How many days after onset is it too late to evacuate submacular hemorrhage secondary to ARMD? Keye L. Wong
12:23 Pneumatic displacement of submacular hemorrhage- a case series Wilson Heriot
12:28 Comparison of Submacular Surgery and Natural History for the Treatment of Large Submacular Hemorrhages from MD John T. Thompson
12:33 Recurrent CNV after Macular Translocation Surgery With 360-degree Peripheral Retinectomy Claxton A. Baer (Winner 2006 B&L Retina Fellows' Forum Research Award)
12:38
Subretinal Surgery for Peripapillary Subretinal Neovascular Membranes Gregg T. Kokame
12:42 Discussion
12:45 Prolonged Choroidal Hypofluorescence following Verteporfin PDT Combined with Intravitreal Triamcinolone Acetate Injection for Age-related CNVM Jeffrey K. Luttrull
12:50 Increased Visual Acuity in Fellow Affected Eyes of Subjects Undergoing Therapy with Intravenous EVIZON™ (Squalamine lactate) for Exudative ARMD Michael Gast
12:55
Two-year Phase II/III Results (IMT002) of a Visual Prosthesis for Treatment of Central Vision Loss due to End-Stage Macular Degeneration Henry L. Hudson
01:00
Discussion
 
02:10
Symposium V: Surgical Devices and Instrumentation (Part 1) Presiding Officer: Mike Trese, Chair: Tarek S. Hassan, Moderator: Claus Eckardt
 
02:10 Evaluation of the Artificial Silicon Retina™ Device for the Treatment of Vision Loss from Retinitis Pigmentosa John S. Pollack
02:15 Chronic retinal chip implant in blind patients with retinitis pigmentosa Gisbert Richard
02:20 Results from a Chronically Implanted 16-Channel Epiretinal Prosthesis in Blind Subjects Robert J. Greenberg
02:25
Discussion
02:28 Shedding More Light on Endoillumination David R. Chow
02:33
Initial Clinical Experience with a Patterned Scanning Laser (PASCAL) for the Treatment of Retinal Diseases Julia A. Haller
02:38 Results of Ophthalmic Surgical Training Using a High-fidelity Surgical Simulator Coupled with a Curriculum Based on Task Breakdown and Analysis Michael Grodin
02:43 Cannulation of the Suprachoroidal Space: Drug Delivery and Pharmacokinetics of Triamcinolone Acetonide and Bevacizumab Timothy W. Olsen
02:48 Enzymatic Alteration of Vitreous Cavity Oxygen Levels Michael T. Trese
02:53 Discussion
02:56 20 Gauge Sutureless Transconjunctival Vitrectomy Daniel Polya
03:01 Transconjunctival 20-G Sutureless Vitrectomy Mikael Sebag
03:06 Discussion
03:09 25 Gauge Vitrectomy: Outcomes and Complications Carl Regillo
03:14 Complications of 25-gauge Vitrectomy Surgery Robert A. Mittra
03:19 A Head-to-Head Intraoperative Clinical Comparison of Flow Rates: Electric vs. Pneumatic 25-gauge High-Speed Vitreous Cutters Tarek S. Hassan
03:24 Discussion
03:27 23-Gauge Vitrectomy as an effective and safe alternative for sutureless vitreous surgery Keith A. Warren
03:31 23-Gauge Vitrectomy in 100 Eyes: Short-Term Visual Outcomes and Complications Harinderjit Singh
03:35 Further experience with 23-gauge transconjunctival vitrectomy Claus Eckardt
03:40 23g Sutureless Vitrectomy: When and Why? Zoran Tomic
03:44
A new 23 Gauge Vitrectomy System George A. Williams
03:49 New Devices for Vitreoretinal Surgery Carl C. Awh
03:54 Discussion
03:57 Surgical Devices and Instrumentation Panel Discussion Moderator: Carl C. Awh
04:15
EVRS Business Meeting
07:20
Coach transportation to Palm Beach Casino
07:30 Casablanca Night at Palm Beach Casino
 
Tuesday, September 12
 
08:00 Opening of continuing Film Projection
 
08:00 Symposium VI: Surgical Devices and Instrumentation (Part 2) Presiding Officer: Suber Huang, Chair: Steve Charles, Moderator: Oswaldo Brasil, Sr.
 
08:00 Comparison Of Wound Leakage Between Straight And Tunnel Scleral Incisions After 25 Gauge Vitrectomy Luiz Hagemann
08:05 The integrity of wound closure after 23 versus 25 gauge sutureless vitrectomy Oswaldo Moura Brasil, Jr.
08:10 Unfavorable Surgical Events in 25 vs. 20 Gauge Vitreous Surgery Saad A. Shaikh
08:15 Comparison of visual recovery time in patients undergoing 20g and 25 gauge vitreous surgery Suber S. Huang
08:20 Discussion
08:25 Vitreous Dynamics: The New Solid Development Concept. Vitreous Flow Analysis in 20, 23 and 25 Gauge Cutters Octaviano Magalhaes
08:30 Fluid dynamics among different 25-gauge systems: principles for use in vitreoretinal surgery Michel E. Farah
08:35 Improved understanding of TSV-25g Vitrectomy system: Qualitative High Speed Video Analysis Of Vitreous Movement Around Aperture of Vitreous Cutters Mark S. Humayun
08:40 Interface Vitrectomy Steve T. Charles
08:45 Passive Removal of Silicone Oil with 25-Gauge Transconjunctival Sutureless Vitrectomy Instruments Ziya Kapran
08:50 Discussion
 
08:55 Symposium VII: Retinal Vascular Disease and Oncology Presiding Officer: Suber Huang, Chair: Steve T. Charles, Moderator: Oswaldo Brasil, Sr.
 
08:55 Reversal of Ischemic CRVO: A Novel Technique of Multiple Retinal Vein Decompression and Chorioretinal Venous Anastomosis Calvin A. Grant
09:00 Radial optic neurotomy plus IVT with and without ILM peeling for CRVO Jose Garcia-Arumi
09:05 Safety Profile of Various Steroids on Retinal Cells In Vitro Baruch D. Kuppermann
09:10 Discussion
09:14 Pegaptanib Sodium for the Treatment of ME Following CRVO John Wells
09:19 Short Term Visual and Anatomic Outcomes Following Intravitreal Bevacizumab for ME Secondary to CRVO Jose A. Roca
09:24 Intravitreal Bevacizumab For Treatment Of ME In Central And BRVO Ajay Dudani
09:29 Ranibizumab (Lucentis) in ischemic CRVO: intermediate OCT and visual results from the RAVE trial Matthew S. Benz
09:34 Discussion
09:38 Retinoblastoma Tumor Vascular Heterogeneity: A Model for Angiogenic Vacular Maturation and Implications for Vascular Targeting Therapy Timothy G. Murray
09:44 Standard and High Resolution Echographic Features of Melanocytoma Amy C. Schefler
09:50 Discussion
10:00 Poster Session (DIABETIC RETINOPATHY/RETINAL VASCULAR DISEASE & ONCOLOGY/MACULAR SURGERY)
 
10:40 Symposium VIII: Diabetic Retinopathy (Part 1) Presiding Officer: J. Fernando Arevalo, Chair: Athanasios Nikolakopoulus, Moderator: Robert L. Avery
 
10:40 Clinical Detection of DME Using the Automated Retinal Imaging System Antonio P. Ciardella
10:45 Factors Influencing Utilization of a Telemedicine Diabetic Retinopathy Assessment Program in the Primary Care Setting Ingrid E. Zimmer-Galler
10:50 Diurnal Variation in Retinal Thickening Measured by OCT Michel J. Shami
10:55 Discussion
10:59 Subthreshold Micropulse Diode Laser Photocoagulation in the treatment of diabetic clinically significant ME Neelakshi Bhagat
11:04 VEGF small interfering (si) RNA, Cand5, for Treatment of DME Jonathan L. Prenner
11:09 Three-Year Results of a Multicenter Clinical Trial of the Fluocinolone Acetonide Intravitreal Implant to Treat DME Dean Eliott
11:14 The I-vation Sustained Release Drug Delivery System and Intravitreal Implant Eugene de Juan, Jr.
11:19 Discussion
11:22 The Effect of the Oral PKC ? Inhibitor Ruboxistaurin on Visual Loss and DME Ronald P. Danis
11:27 The Effect of an Epiretinal Membrane on IVT Treatment for DME Parin S. Gohel
11:32 Predictive factors for visual outcome after IVT acetonide injection for DME Rishi Singh
11:37 Discussion
11:40 Pegaptanib Sodium in Diabetic Retinopathy: Improvements in DME, RNV, and Severity of Diabetic Retinopathy Victor Hugo Gonzalez
11:45 OCT Following Pegaptanib Therapy in Diabetics: a Bioanatomic Study of DME David R. Guyer
11:50 Intravitreal injection versus systemic Bevacizumab(Avastin) Therapy for DME Murat Oncel
11:55 Discussion
11:58 Interim Results of the R.E.A.D. Study: Ranibizumab for Edema of the Macula in Diabetes Diana V. Do
12:03 Primary Intravitreal Bevacizumab (Avastin) for the Treatment of DME: Results of the Pan-American Collaborative Retina Study Group J. Fernando Arevalo
12:08 Intravitreal Bevacizumab (Avastin) in the Treatment of PDR Robert L. Avery
12:15 Injection of Intravitreal Avastin before Vitrectomy Surgery in the treatment of Severe PDR Stanislao Rizzo
12:20 Discussion
12:23 A Simple Predictor of Vitrase® Efficacy for BCVA Improvement in Patients with Diabetes and Severe Vitreous Hemorrhage Abdhish R. Bhavsar
12:29 Vitrase for Vitreous Hemorrhage Revisited Michael A. Singer
12:35 Discussion
12:38 25 Gauge Vitrectomy for Advanced PDR: A Consecutive Case Series Including Complex RD Firas M. Rahhal
12:44 Diabetic traction detachment treated with bimanual 25g sutureless surgery (Is silicon oil necessary?) Athanasios Nikolakopoulos
12:50 Reoperation After Diabetic Vitrectomy: Rate, Indications, Visual Outcomes, and Complications in an Urban Academic Medical Center Julie Gasperini
12:56 Posterior Juxtascleral Injection of Triamcinolone Acetonide for Cases of Diabetic ME Unresponsive or Unamenable to Laser Treatment Franco M. Recchia
01:02 Vitrectomy for DME: study design and preliminary results of VIDE Study, an Italian clinical trial Barbara Parolini
01:08 Discussion
 
02:15 Symposium VIII: Diabetic Retinopathy (Part 2)
 
02:15 Panel Discussion Moderator: Harry W. Flynn Panelists: Tarek S. Hassan, Rodrigo Jorge, Frank HJ Koch, Brooks W. McCuen, II, Robert P. Murphy, Georgiy Stolyarenko
 
02:45 Symposium IX: Macular Surgery Presiding Officer: Claudio Azzolini , Chair: Fabio Patelli , Moderator: Keye Wong
 
02:45 Posterior RD and retinoschisis without a MH in highly myopic eyes: Clinical findings and management Hassan Mortada
02:51 Myopic Traction Maculopathy: A Slowly Progressive and Treatable Disease Giacomo A. Panozzo
02:57 Discussion
03:02 25 Gauge Macular Surgery: Results and Complications Fabio Patelli
03:08 Surgical Treatment of Macular Pucker: Multicenter Clinical Trial Claudio Azzolini
03:14 Outcomes of 25 gauge transconjonctival membrane peeling combined with sutureless phaco/IOL surgery Jean-Paul Berrod
03:20 Discussion
03:25 Combined Phacoemulsification and Vitrectomy for MH Repair Ioannis Theocharis
03:31 Prospective randomized clinical trial comparing face down position and semi seated position after surgery for idiopathic full-thickness MH Alexandre Guillaubey
03:37 ILM peeling prevents late reopening of closed MH Thierry C. Verstraeten
03:43 25 Gauge Transconjunctival Sutureless Vitrectomy for MH repair: how can we resolve technique-related problems? Federica Genovesi-Ebert
03:49 Results of Surgical Management of Senile MH by 25-Gauge Trans-Conjunctival Sutureless Vitrectomy Compared to Standard Vitrectomy Systems C. Christopher Brown
03:55 Idiopathic MH Following Pars Plana Vitrectomy For RD Francesco Boscia
04:01 Discussion
06:30 Closing Night Festivities
06:30 Film Festival Awards Ceremony / Gala Dinner / Nightclub
 
Wednesday, September 13
 
08:00 Opening of continuing Film Projection
 
08:00 Symposium X: Retinal Detachment Presiding Officer: Giampaolo Gini, Chair: Klaus Lucke, Moderator: Masoud Soheilian
 
08:00 The Value and Cost-Effectiveness of Vitreoretinal Interventions Gary C. Brown
08:06 Rhegmatogenous RD in myopic eyes after LASIK. Characteristics, surgical management and functional outcomes Anna Boixadera
08:12 Use of 25-Gauge Pars Plana Vitrectomy Surgery for Primary Repair of Rhegmatogenous RD Amitabh Bharadwaj
08:18 Discussion
08:20 Visual and Anatomic Outcomes of Pneumatic Retinopexy Daniel B. Roth
08:26 Results of Pneumatic Retinopexy in Phakic Eyes - A Prospective Comparison of the Clinical Trial Group Inclusion Criteria and Extended Criteria Stephen M. Conti
08:32 Discussion
08:35 Optic Pit RD - Attempt at a Unifying Theory Klaus Lucke
08:41 Multiples Macular RD After successful Buckle Surgery: Infrared, Autofluorescence, oct and Microperimetric features Francesco Faraldi
08:47 Discussion
08:50 Incidence of RD after macular surgery: a retrospective study of 634 cases Catherine Creuzot
08:56 Cataract Surgery and Vitrectomy for PVR: comparaisons Between Internal Tamponades and Lens Removal Techniques Marcio B. Nehemy
09:02 Triamcinolone Acetonide in Silicone-filled Eyes as Adjunctive Treatment for PVR: A Randomized Clinical Trial Hamid Ahmadieh
09:08 Effect of Intraoperative 5-Fluorouracil and Low Molecular Weight Heparin on the Outcome in High-Risk PVR Guruprasad S. Ayachit
09:14 Primary Vitrectomy in the Treatment of RD in Highly Myopic Eyes with Axial Length Over 30mm Gregoire Minoyan
09:20 Discussion
 
09:23 Symposium XI: Trauma Presiding Officer: Giampaolo Gini, Chair: Klaus Lucke , Moderator: Masoud Soheilian
 
09:23 Microbial Isolates and Sensitivities in Posterior-Segment Intraocular Foreign Body Injuries: A 10-year Review Samuel B. Barone
09:30 Prophylaxis of Acute Post-Traumatic Bacterial Endophthalmitis with and without Intraocular Antibiotic injection Masoud Soheilian
09:37 Intraocular Foreign Body Removal at Walter Reed Army Medical Center During Operations Iraqi and Enduring Freedom Marcus Colyer
09:44 Management of traumatic RD associated with open globe injuries Giampaolo Gini
09:51 Discussion
10:00 Poster Session (PEDIATRIC AND INFLAMMATORY DISEASE/HEREDITARY RETINAL DISEASE & GENETICS/RETINAL DETACHMENT/TRAUMA)
 
10:40 Symposium XII: Pediatrics and Inflammatory Disease Presiding Officer: Harry Flynn, Chair: Silvia Bopp, Moderator: Dan Martin
 
10:40 Screening for retinopathy in the pediatric sickle cell patient population Harmeet Gill
10:46 PFV: Clinical Spectrum and Therapeutic Approach Silvia Bopp
10:52 Discussion
10:57 Telemedicine Screening for Retinopathy of Prematurity: The Stanford Experience (SUNDROP) Steven R. Sanislo
11:03 Safety and efficacy of intravitreal bevacizumab for retinopathy of prematurity Hugo Quiroz-Mercado
11:09 Anti-VEGF Therapy for Pediatric Retinopathies: Which Case is the Right Case? Kimberly A. Drenser
11:15 Discussion
11:20 Endophthalmitis in the Newborn Kristen Hartley
11:26 A 2006 Update on the Risks Associated with Intravitreous Injection and Guidelines for Safe Administration Emmett T. Cunningham
11:32 Acute-onset Endophthalmitis Following Clear Corneal Cataract Surgery (1996-2005): Clinical Features, Microbiology and Visual Outcomes Geeta Lalwani
11:38 Early Onset Endophthalmitis Caused by Aspergillus Species Following Cataract Surgery Harry W. Flynn, Jr.
11:44 Discussion
11:47 25-Gauge Vitrectomy Management of Severe Post-Cataract Surgery Endophthalmitis Flavio A. Rezende
11:53 Complete and Early Vitrectomy for Eyes with Postoperative Endophthalmitis Ferenc Kuhn
11:59 In-office And Bedside Sutureless Vitrectomy for The Diagnosis Of Uveitis Robert G. Josephberg
12:05 Three-Year Results of a Multi-Center Clinical Trial of Fluocinolone Acetonide Intravitreal Implants to Treat Posterior Uveitis Daniel F. Martin
12:11 Discussion
 
12:15 Symposium XIII: Future Directions Presiding Officer: Harry W. Flynn, Chair: Silvia Bopp, Moderator: Daniel F. Martin
 
12:15 Sub-retinal injection of Bevacizumab (Avastin) in treating neovascular ARMD, 25 gauge approach Ehab El-Rayes
12:20 Rationale for Genistein in the Prevention and Treatment of Diabetic Retinopathy Michael J. Cooney
12:25 Application of Proteomic Analysis to Characterize the Molecular Pathways of the Vitreous and Retina in Health and Disease Bert M. Glaser
12:30 Ultra-Wide Angle Fluorescein Angiographic Evaluation of the Retinal Periphery in the Management of Retinal Vascular Diseases Steven D. Schwartz
12:35 New Pharmacologic Treatments for Retinal Disease: A Venture Capital Perspective Gilbert H. Kliman
12:42 Discussion
12:47 Closing remarks